
1. Nat Commun. 2017 Jan 31;8:14193. doi: 10.1038/ncomms14193.

SC83288 is a clinical development candidate for the treatment of severe malaria.

Pegoraro S(1), Duffey M(2)(3), Otto TD(4), Wang Y(2)(3), Rösemann R(5),
Baumgartner R(1), Fehler SK(1)(2)(3), Lucantoni L(6), Avery VM(6), Moreno-Sabater
A(7)(8), Mazier D(7)(9), Vial HJ(10), Strobl S(5), Sanchez CP(2)(3), Lanzer
M(2)(3).

Author information: 
(1)4SC AG, Am Klopferspitz 19a, 82152 Martinsried, Germany.
(2)Department of Infectious Diseases, Parasitology, Universitätsklinikum
Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.
(3)German Center for Infection Research (DZIF), partner site Heidelberg, 69120
Heidelberg, Germany.
(4)Parasite Genomics, Wellcome Trust Sanger Institute, Wellcome Genome Campus,
Hinxton CB10 1SA, UK.
(5)4SC Discovery GmbH, Am Klopferspitz 19a, 82152 Martinsried, Germany.
(6)Eskitis Institute for Drug Discovery, Griffith University, Don Young, Nathan
Queensland 4111, Australia.
(7)Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre 
d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital,
F-75013 Paris, France.
(8)AP-HP, Hôpital St Antoine, Service de Parasitologie-Mycologie, F-75012 Paris, 
France.
(9)AP-HP, Groupe hospitalier La Pitié-Salpêtrière, Service de
Parasitologie-Mycologie, F-75013 Paris, France.
(10)Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR
5235, Université Montpellier II, cc107, Place Eugène Bataillon, 34095
Montpellier, France.

Erratum in
    Nat Commun. 2017 Apr 06;8:15273.

Severe malaria is a life-threatening complication of an infection with the
protozoan parasite Plasmodium falciparum, which requires immediate treatment.
Safety and efficacy concerns with currently used drugs accentuate the need for
new chemotherapeutic options against severe malaria. Here we describe a medicinal
chemistry program starting from amicarbalide that led to two compounds with
optimized pharmacological and antiparasitic properties. SC81458 and the clinical 
development candidate, SC83288, are fast-acting compounds that can cure a P.
falciparum infection in a humanized NOD/SCID mouse model system. Detailed
preclinical pharmacokinetic and toxicological studies reveal no observable
drawbacks. Ultra-deep sequencing of resistant parasites identifies the
sarco/endoplasmic reticulum Ca2+ transporting PfATP6 as a putative determinant of
resistance to SC81458 and SC83288. Features, such as fast parasite killing, good 
safety margin, a potentially novel mode of action and a distinct chemotype
support the clinical development of SC83288, as an intravenous application for
the treatment of severe malaria.

DOI: 10.1038/ncomms14193 
PMCID: PMC5290327
PMID: 28139658  [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing financial
interests.

